Advertisement

Breast Cancer Research and Treatment

, Volume 123, Issue 1, pp 9–24 | Cite as

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

  • Rob Riemsma
  • C. A. Forbes
  • A. Kessels
  • K. Lykopoulos
  • M. M. Amonkar
  • D. W. Rea
  • J. Kleijnen
Review

Abstract

To undertake a systematic review of three first-line treatments (letrozole, anastrozole and exemestane) for hormone sensitive advanced or metastatic breast cancer (MBC) in post-menopausal women. We searched six databases from inception up to January 2009 for relevant trials regardless of language or publication status. Randomised controlled clinical trials assessing the safety and efficacy of first-line AIs for post-menopausal women with hormone receptor-positive (HR+, i.e. ER+ and/or PgR+) with or without ErbB2 (HER2)-positive MBC, who have not received prior therapy for advanced or metastatic disease were included. Where meta-analysis using direct or indirect comparisons was considered unsuitable for some or all of the data, we employed a narrative synthesis method. Four studies (25 papers) met the inclusion criteria. From the available evidence, it was possible to directly compare the three AIs with tamoxifen. In addition, by using a network meta-analysis it was possible to compare the three AIs with each other. Based on direct evidence, letrozole seemed to be significantly better than tamoxifen in terms of time-to-progression (TTP) (HR = 0.70 (95% CI: 0.60, 0.82)), objective response rate (RR = 0.65 (95% CI: 0.52, 0.82)) and quality-adjusted time without symptoms or toxicity (Q-Twist difference = 1.5; P < 0.001). Exemestane seemed significantly superior to tamoxifen in terms of objective response rate (RR = 0.68 (95% CI: 0.53, 0.89)). Anastrozole seemed significantly superior to tamoxifen in terms of TTP in one trial (HR = 1.42 (95% CI: 1.15, NR)), but not in the other (HR = 1.01 (95% CI: 0.87, NR)). In terms of adverse events, no significant differences were found between letrozole and tamoxifen. Tamoxifen was associated with significantly more serious adverse events in comparison with exemestane (OR = 0.61 (95% CI: 0.38, 0.97)); while exemestane was associated with significantly more arthralgia in comparison with tamoxifen (OR = 2.33 (95% CI: 1.07, 5.11)). Anastrozole was associated with significantly more total adverse events (OR = 1.04 (95% CI: 1.00, 1.09)) and hot flushes (OR = 1.39 (95% CI: 1.03, 1.89)) in comparison with tamoxifen in one trial; however, the other trial showed no significant differences in adverse events between anastrozole and tamoxifen. The indirect comparison of AIs with each other in women with post-menopausal, hormone sensitive advanced or MBC showed that letrozole and exemestane were better in terms of objective response rate than anastrozole; while the more clinically relevant outcomes overall survival (OS) and progression-free survival (PFS) showed no significant differences between AIs. OS and PFS showed no significant differences between AIs and hence based on these results a class effect for all AIs is possible. However, these results are based on indirect comparisons and a network analysis for which the basic assumptions of homogeneity, similarity and consistency were not fulfilled. Therefore, despite the fact that these are the best available data, the results need to be interpreted with appropriate caution. Head-to-head comparisons between letrozole, anastrozole and exemestane in the first-line MBC setting are warranted.

Keywords

Systematic review Aromatase inhibitors First-line treatment Hormone sensitive advanced or metastatic breast cancer 

Notes

Acknowledgements

The project was funded by GlaxoSmithKline. Konstantinos Lykopoulos and Mayur Amonkar both work for GlaxoSmithKline. Daniel Rea received honoraria from Pfizer, Novartis and Astra Zeneca and he received research funding to his institution from Pfizer, Novartis and Astra Zeneca, and provided consultancy to Novartis, Pfizer and Astra Zeneca.

Conflict of interest statement

Rob Riemsma, Carol Forbes, Fons Kessels, and Jos Kleijnen have no other conflicts of interest. Furthermore, RR, CF, FK and JK had ultimate editorial control of the manuscript.

References

  1. 1.
    Cancer Research UK (2009) CancerStats key facts on breast cancer. http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/?a=5441. Accessed 25 Aug 2009
  2. 2.
    Cancer Research UK (2009) UK breast cancer mortality statistics. http://info.cancerresearchuk.org/cancerstats/types/breast/mortality/?a=5441. Accessed 25 Aug 2009
  3. 3.
    National Institute for Health and Clinical Excellence (2009) Draft scope for the appraisal of lapatinib for the first-line treatment of metastatic hormone sensitive breast cancer (Issue Date April 2009), 25 June 2009Google Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717Google Scholar
  5. 5.
    Gibson LJ, Dawson CK, Lawrence DH, Bliss JM (2007) Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev (1):CD003370Google Scholar
  6. 6.
    Howell A, Dowsett M (2004) Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res 6(6):269–274CrossRefPubMedGoogle Scholar
  7. 7.
    Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M et al (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26:1671–1676CrossRefPubMedGoogle Scholar
  8. 8.
    Geisler J, Haynes B, Anker G (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer evaluated in a randomized, cross-over study. J Clin Oncol 20:751–757CrossRefPubMedGoogle Scholar
  9. 9.
    National Institute for Clinical Excellence (2002) Guidance on the use of trastuzumab for the treatment of advanced breast cancer. Technology Appraisal Guidance no. 34. London, NICE. http://www.nice.org.uk/nicemedia/live/11445/32313/32313.pdf. March 2002
  10. 10.
    Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98CrossRefPubMedGoogle Scholar
  11. 11.
    Johnston SR, Pegram M, Press M, Pippen J, Pivot X, Gomez HL, et al (2008) Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. In: San Antonio Breast Cancer Symposium, 31st Annual SABCS, 10–14 December 2008Google Scholar
  12. 12.
    Kaufman B (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). In: European Society for Medical Oncology (ESMO) Congress, 29 September to 3 October, Istanbul, TurkeyGoogle Scholar
  13. 13.
    Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews of interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, OxfordGoogle Scholar
  14. 14.
    Bücher HC, Guyatt GH, Griffiths LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683–691CrossRefPubMedGoogle Scholar
  15. 15.
    Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG (2009) Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 14(7):2CrossRefGoogle Scholar
  16. 16.
    Nabholtz JM, Bonneterre J, Buzdar AU, Thürlimann BJK, Robertson JFR, Webster A et al (1999) Preliminary results of two multi-center trials comparing the efficacy and tolerability of arimidex (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 57(1):31Google Scholar
  17. 17.
    Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thurlimann B (2003) Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39(12):1684–1689CrossRefPubMedGoogle Scholar
  18. 18.
    Nabholtz JM (2003) Advanced breast cancer updates on anastrozole versus tamoxifen. J Steroid Biochem Mol Biol 86(3–5):321–325CrossRefPubMedGoogle Scholar
  19. 19.
    Bonneterre J, Buzdar A, Nabholtz J-M, Robertson JFR, Thürlimann B, Von Euler M et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 92(9):2247–2258CrossRefPubMedGoogle Scholar
  20. 20.
    Bonneterre JM, Nabholtz JM, Buxdar A, Robertson J, Thürlimann B (2002) Anastrozole compared with tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer—survival analyses. Ann Oncol 13:47CrossRefGoogle Scholar
  21. 21.
    Buzdar A, Nabholtz JM, Robertson JF, Thürlimann BJK, Bonneterre J, Von Euler M, Steinberg M, Webster A (2000) Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women: combined analysis from two identically designed multicenter trials. Proc Am Soc Clin Oncol 19:154a (abstr 609D). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=200259
  22. 22.
    Buzdar A, Bonneterre J, Nabholtz JM, Robertson JFR, Thürlimann B, Von Euler M et al (2000) Anastrazole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women: findings highlight the importance of receptor status assessment prior to treatment initiation. Ann Oncol 11(Suppl-4):25Google Scholar
  23. 23.
    Thürlimann B, Nabholtz JM, Bonneterre J, Buzdar AU, Robertson JFR, Webster A et al (1999) Preliminary results of two comparative multicentre clinical trials comparing the efficacy and tolerability of Arimidex TM (anastrozole) and tamoxifen (TAM) in postmenopausal women with advanced breast cancer (ABC). The Breast 8(4):214Google Scholar
  24. 24.
    Thürlimann BJK, Bonneterre J, Buzdar A, Nabholtz J-M, Robertson FR, Sahmoud T (2001) First line endocrine therapy in postmenopausal patients with advanced breast cancer and visceral metastases: anastrozole (Arimidex) versus tamoxifen. Proc Am Soc Clin Oncol 20 (abstr 1835). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10&abstractID=1835
  25. 25.
    Robertson J, Buzdar A, Nabholtz JM, Thürlimann B, Bonneterre J, Von Euler M (2000) Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women—prospective combined analysis from two international trials. Eur J Cancer 36(Suppl-5):S88Google Scholar
  26. 26.
    Robertson JFR, on behalf of the Arimidex 1st-Line Study Group (2008) Anastrozole (Arimidex) versus tamoxifen as 1st-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women—combined analysis from two identically designed multicenter trials. Br J Cancer 83:39Google Scholar
  27. 27.
    AstraZeneca P (2001) Randomised, double-blind trials to compare the efficacy and safety of Arimidex (anastrozole 1 mg daily) with tamoxifen (20 mg daily) as first-line therapy for advanced breast cancer in postmenopausal women: safety and survival update 2001 (1033IL/0030 and 1033IL/0027). Trial Report. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinicaltrials/resources/pdf/8609896
  28. 28.
    Vergote I, Thürlimann B (2001) First-line endocrine therapy in postmenopausal patients with advanced breast cancer and visceral metastases: anastrozole versus tamoxifen. Eur J Cancer 37:191CrossRefGoogle Scholar
  29. 29.
    Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767PubMedGoogle Scholar
  30. 30.
    Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757PubMedGoogle Scholar
  31. 31.
    Mouridsen HT (2007) Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 105(Suppl-1):19–29CrossRefPubMedGoogle Scholar
  32. 32.
    Irish W, Sherrill B, Cole B, Gard C, Glendenning GA, Mouridsen H (2005) Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 16(9):1458–1462CrossRefPubMedGoogle Scholar
  33. 33.
    Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19(10):2596–2606PubMedGoogle Scholar
  34. 34.
    Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 21(11):2101–2109CrossRefPubMedGoogle Scholar
  35. 35.
    Mouridsen H, Chaudri-Ross HA (2004) Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist 9(5):497–506CrossRefPubMedGoogle Scholar
  36. 36.
    Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA et al (2004) Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9(5):489–496CrossRefPubMedGoogle Scholar
  37. 37.
    Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA et al (2003) Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21(10):1967–1972CrossRefPubMedGoogle Scholar
  38. 38.
    Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L et al (2008) Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 26(16):2653–2658CrossRefPubMedGoogle Scholar
  39. 39.
    Smith IE (2003) Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 86(3–5):289–293CrossRefPubMedGoogle Scholar
  40. 40.
    Smith R, Sun Y, Garin A, Fein A, Sleeboom HP, Chaudri H et al (2000) Femara (letrozole) showed significant improvement in efficacy over tamoxifen as first-line treatment in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 64:27Google Scholar
  41. 41.
    Bonneterre J, Thurlimann BJK, Robertson JFR (1999) Preliminary results of a large comparative multi-centre clinical trial comparing the efficacy and tolerability of Armidex (Anastrozole) and Tamoxifen (TAM) in postmenopausal women with advanced breast cancer (ABC). Eur J Cancer 35(Suppl-4):S313CrossRefGoogle Scholar
  42. 42.
    Vergote I, Bonneterre J, Thurlimann B, Robertson J, Krzakowski M, Mauriac L et al (2000) Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 36(Suppl-4):S84–S85CrossRefPubMedGoogle Scholar
  43. 43.
    AstraZeneca P (1999) A randomised, double-blind, double-dummy trial to compare the efficacy and safety of Arimidex (ZD1033 1 mg daily) with tamoxifen (20 mg daily) as first-line therapy for advanced breast cancer in postmenopausal women (1033IL/0027). Trial Report. http://www.astrazenecaclinicaltrials.com/_mshost2715844/content/content/resources/media/2958892/1033il_0027.pdf
  44. 44.
    AstraZeneca P (1999) A randomized, double-blind trial to compare the efficacy and safety of anastrozole (Arimidex 1 mg daily) with tamoxifen citrate (20 mg daily) as first-line therapy for advanced breast cancer in postmenopausal women (1033IL/0030). Trial Report. http://www.astrazenecaclinicaltrials.com/_mshost2715844/content/content/resources/media/2958892/1033il_0030_target.pdf
  45. 45.
    Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T et al (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26(30):4883–4890CrossRefPubMedGoogle Scholar
  46. 46.
    Dirix L, Piccart MJ, Lohrisch C, Beex L, Nooij M, Cameron D, et al (2001) Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 20:29aGoogle Scholar
  47. 47.
    Maung K (2001) Randomized phase II trial comparing exemestane to tamoxifen for first-line hormonal therapy of postmenopausal patients with metastatic breast cancer. Clin Breast Cancer 2(2):110–112Google Scholar
  48. 48.
    National Cancer Institute, Paridaens R (1996) Phase II/III randomised study of first-line hormonal therapy with exemestane versus tamoxifen in postmenopausal women with locally recurrent metastic breast cancer. Study NCT00002777. http://www.cancer.gov/clinicaltrials/EORTC-10951
  49. 49.
    Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al (2000) Promising activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (pts): final results of an EORTC rendomised phase II trial. Breast Cancer Res Treat 64:52Google Scholar
  50. 50.
    Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14(9):1391–1398CrossRefPubMedGoogle Scholar
  51. 51.
    Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M, Mattiacci M-R (2004) First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC breast group. J Clinic Oncol (ASCO annual meeting proceedings (post-meeting edition), vol 22, no 14S (July 15 Suppl):515. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2103
  52. 52.
    ClinicalTrials.gov (2008) Exemestane Compared with Tamoxifen in Treating Women with locally recurrent Metastic Breast Cancer. Randomized Phase II Study in first line hormonal treatment for metastic breast cancer with exemestane or tamoxifen in postmenopausal patients. Study NCT00002777Google Scholar
  53. 53.
    Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E et al (2003) Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 26(3):317–322CrossRefPubMedGoogle Scholar
  54. 54.
    Altundag K, Ibrahim NK (2006) Aromatase inhibitors in breast cancer: an overview. Oncologist 11(6):553–562CrossRefPubMedGoogle Scholar
  55. 55.
    Berry J (2005) Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 27(11):1671–1684CrossRefPubMedGoogle Scholar
  56. 56.
    Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A et al (2006) Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 94:1789–1796CrossRefPubMedGoogle Scholar
  57. 57.
    Perez CR, Alberola C, V, Calabresi F, Michel RT, Santos R, Delozier T, et al (1994) Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5(Suppl):24Google Scholar
  58. 58.
    Thurlimann B, Beretta K, Bacchi M, Castiglione-gertsch M, Goldhirsch A, Jungi WF et al (1996) First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 7(5):471–479PubMedGoogle Scholar
  59. 59.
    Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D (2007) When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99(6):428–432CrossRefPubMedGoogle Scholar
  60. 60.
    Carroll KJ (2007) Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 6(2):99–113CrossRefPubMedGoogle Scholar
  61. 61.
    EMEA (2008) Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95 REV.3) methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials for registration. EMEA Google Scholar
  62. 62.
    Chakravarty A, Sridhara R (2008) Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res 17(5):515–518CrossRefPubMedGoogle Scholar
  63. 63.
    Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. Br Med J 338:B1147CrossRefGoogle Scholar
  64. 64.
    Kataja V, Castiglione M (2008) Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Supp 2):ii11–ii13Google Scholar
  65. 65.
    National Comprehensive Cancer Network (2009) Clinical practice guidelines in oncology. 2009. Report No.: V.1.2010. http://www.nccn.org
  66. 66.
    National Institute for Health and Clinical Excellence (2009) Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. NICE technology appraisal guidance 112. Report No.: Issue date: November 2006. Review date: June 2009. http://www.nice.org.uk/nicemedia/live/11598/33642/33642.pdf

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Rob Riemsma
    • 1
  • C. A. Forbes
    • 1
  • A. Kessels
    • 2
  • K. Lykopoulos
    • 3
  • M. M. Amonkar
    • 4
  • D. W. Rea
    • 5
  • J. Kleijnen
    • 1
    • 2
  1. 1.Kleijnen Systematic Reviews Ltd.YorkUK
  2. 2.School for Public Health and Primary Care (CAPHRI)Maastricht UniversityMaastrichtThe Netherlands
  3. 3.GlaxoSmithKlineBrentfordUK
  4. 4.GlaxoSmithKlinePhiladelphiaUSA
  5. 5.Institute for Cancer StudiesUniversity of BirminghamBirminghamUK

Personalised recommendations